Cited by 312SARS-CoV-2 and COVID-19 ResearchCOVID-19 Impact on ReproductionVaccine Coverage and Hesitancy

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Open access
Dagan, Noa, Barda, Noam, Biron-Shental, Tal, Makov-Assif, Maya, Key, Calanit, Kohane, Isaac S., Hernán, Miguel A., Lipsitch, Marc +3 more·2021·Nature Medicine

Published version of a preprint

Abstract

To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89-100%) for any documented infection, 97% (91-100%) for infections with documented symptoms and 89% (43-100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01490-8

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A recent observational study in a cohort of 10,861 pregnant women showed that BNT162b2 had 96% effectiveness in the prevention of COVID-19.

    “A recent observational study in a cohort of 10,861 pregnant women showed that BNT162b2 had 96% effectiveness in the prevention of COVID-19.115”

    From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [115]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Barda, N., Dagan, N. & Balicer, R. D. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. Reply. N. Engl. J. Med. 384, 1970 (2021).

Cited by

Sorted by citations

Authors
Dagan, N., Barda, N., Biron-Shental, T., Makov-Assif, M., Key, C., Kohane, I. S., Hernán, M. A., Lipsitch, M., Hernandez-Diaz, S., Reis, B. Y., & Balicer, R. D.
Affiliations
  • Ben-Gurion University of the Negev (IL)
  • Clalit Health Services (IL)
  • Harvard University (US)
  • Boston Children's Hospital (US)
Corresponding author
Balicer, Ran D.
Venue
Nature Medicine
Published
2021-09-07
Volume
27
Issue
10
Pages
1693-1695
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3180834485
Cited by
312
References
13
Citations by year
2026: 12 · 2025: 27 · 2024: 38 · 2023: 86 · 2022: 130 · 2021: 19
FWCI
21.68
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion)
  • Research Square (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
Funders
  • Ivan and Francesca Berkowitz Family Living Laboratory at Harvard Medical School
  • Morris-Singer Fund
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Obstetrics and Gynecology › COVID-19 Impact on Reproduction
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords
BNT162b2 mRNA vaccine, COVID-19 vaccines, pregnancy, vaccine effectiveness, COVID-19 pandemic, COVID-19 hospitalization, maternal immunization
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Female, Humans, Pregnancy, Pregnancy Complications, Infectious, Cohort Studies, Incidence, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review